ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
treatment of severe calcification in coronary arteries prior to stenting. The TECTONIC Coronary Artery Disease (“CAD”) Intravascular Lithotripsy (IVL) clinical trial will enroll up to 335 people in 47 sites in the United States. The company's investigational Coronary IVL technology builds upon its existing vascular portfolio, part of the Medical Devices segment, and is designed to address the challenges of currently available IVL systems. After the announcement yesterday, Abbott shares edged up 0.7%, finishing at $127.21. The company presently offers a range of treatment solutions, including optical coherence tomography (OCT) imaging technology, which assesses coronary arteries and detects calcium buildup to help physicians identify the arteries that could benefit from plaque modification. Abbott's advanced technologies are designed to ensure complete vascular support, including artery assessment, preparation and treatment. We expect the market sentiment toward ABT stock to remain
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise [Seeking Alpha]Seeking Alpha
- Abbott Laboratories (NYSE:ABT) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns? [Yahoo! Finance]Yahoo! Finance
- Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation [Yahoo! Finance]Yahoo! Finance
- Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial FibrillationPR Newswire
ABT
Earnings
- 10/15/25 - In-Line
ABT
Sec Filings
- 12/23/25 - Form 3
- 12/19/25 - Form 3
- 12/12/25 - Form 4
- ABT's page on the SEC website